← Back to Search

Virus Therapy

JCXH-105 Vaccine for Shingles (JCXH-105 Trial)

Phase 1
Waitlist Available
Research Sponsored by Immorna Biotherapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age: 50 to 69 years of age, inclusive, at screening.
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1 - day 241
Awards & highlights

JCXH-105 Trial Summary

This trial will test a new vaccine to prevent Shingles. Participants will be randomly given either the new vaccine or the current vaccine.

Who is the study for?
This trial is for healthy men and women aged 50 to 69 who have stable health without significant active or chronic diseases. They must not be on systemic antiviral therapy, have no recent vaccines, and agree not to take any herpes zoster vaccine during the study. Individuals with a history of shingles, immunosuppression, or certain heart conditions after mRNA vaccination are excluded.Check my eligibility
What is being tested?
The trial tests JCXH-105, an srRNA-based vaccine against Shingles (Herpes Zoster), compared to Shingrix as an active control. Participants will randomly receive one of these two vaccines to evaluate safety and immune response effectiveness.See study design
What are the potential side effects?
While specific side effects for JCXH-105 aren't listed here, typical vaccine-related side effects may include pain at the injection site, fatigue, headache, muscle pain, chills, fever and nausea. Serious side effects could involve allergic reactions or more severe responses.

JCXH-105 Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 50 and 69 years old.

JCXH-105 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1 - day 241
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1 - day 241 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
AE frequency
Injection site reaction
Medically attended AE frequency
+3 more
Secondary outcome measures
Cellular immunogenicity of the JCXH-105 and Shingrix vaccine

JCXH-105 Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Investigational ProductExperimental Treatment1 Intervention
Participants randomized to this arm will be given the investigational product (JCXH-105).
Group II: Active ControlActive Control1 Intervention
Participants randomized to this arm will be given the FDA approved Shingrix.

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Immorna Biotherapeutics, Inc.Lead Sponsor
3 Previous Clinical Trials
419 Total Patients Enrolled
ICON plcIndustry Sponsor
80 Previous Clinical Trials
25,071 Total Patients Enrolled

Media Library

JCXH-105 (Virus Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05871541 — Phase 1
Shingles Research Study Groups: Investigational Product, Active Control
Shingles Clinical Trial 2023: JCXH-105 Highlights & Side Effects. Trial Name: NCT05871541 — Phase 1
JCXH-105 (Virus Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05871541 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this clinical trial permit applicants below the age of 30?

"This medical experiment is seeking participants aged between 50 and 69 years."

Answered by AI

Could I potentially become a participant in this experiment?

"Eligibility for this trial is limited to individuals between the ages of 50 and 69 who have shingles. The total number of patients accepted into this experiment will be 75."

Answered by AI

Is this investigation still recruiting participants?

"According to the information published on clinicaltrials.gov, this research is currently recruiting participants. It was initially made available in May of 2023 and its most recent update occurred on 12th of that same month."

Answered by AI

How hazardous is utilization of this Investigational Product to human health?

"At this stage in the clinical trial process, limited data exists to support Investigational Product's safety and efficacy. Therefore, it was given a score of 1."

Answered by AI

How many participants are undergoing treatment as part of this research initiative?

"Affirmative. On clinicaltrials.gov, it is indicated that this medical research has opened recruitment on May 1st 2023 and was last updated recently on the 12th of May in the same year. 75 subjects are needed across 3 different sites."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
A First-in-Human Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine
2023. "A First-in-Human Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05871541.
~41 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top